Ireland
--:--IST
Enrolling by invitation Not applicable

Sex-difference in Response to Resistance Exercise and Training

NCT07692815 · tracked via the Priya Life Science Belgium tracker
Phase
Not applicable
Started
2026-02-02
Last updated
2026-07-09

Condition(s) studied

MaleFemaleHealthy Adult

Investigational drug(s) / intervention(s)

Resistance exercise on a leg extension machineResistance training on a leg extension machineBlood samplesVastus lateralis biopsyBody composition analysisOne repetition maximum (1-RM)Muscle thickness of the vastus lateralis

Resistance exercise on a leg extension machine: Supervised resistance exercise consisting exclusively of knee extension exercise on a leg extension machine. Acute exercise included 6 sets of 10 repetitions at 80% of one-repetition maximum (1RM).

Resistance training on a leg extension machine: Supervised resistance training consisting exclusively of knee extension exercise on a leg extension machine. Chronic exercise included 6 sets of 10 repetitions at 80% of one-repetition maximum (1RM). The program was carried out over 8 weeks (3x/week).

Blood samples: Blood samples were taken from the antecubital vein before and immediately after an acute resistance exercise session, and after the chronic resistance training period.

Vastus lateralis biopsy: Biopsy were taken in the vastus lateralis before and immediately after an acute resistance exercise session, and after the chronic resistance training period.

Body composition analysis: Body composition analysis using dual-energy X-ray absorptiometry (DXA) before and after the chronic resistance training period.

One repetition maximum (1-RM): One repetition maximum (1-RM) assessment before, after 4 weeks of training and at the end the chronic resistance training period.

Muscle thickness of the vastus lateralis: Muscle thickness of the vastus lateralis assessed by ultrasonography before and after the chronic resistance training period.

Study summary

Sex-Difference in Response to Resistance Exercise and Training

Given the importance of muscular strength for athletic performance as well as for daily activities in the general population-including clinical populations-and the lack of data in both men and women, the aim of this study is to compare neuromuscular, intramuscular, and systemic adaptations in men and women in response to both acute and chronic resistance exercise.

Specifically, the investigators will test the hypotheses that:

the neuromuscular response to resistance exercise, including corticospinal excitability and motor unit activation patterns, differs between men and women; the hormonal response and exosome release following resistance exercise are reduced in women compared to men.

Participants (n = 15 per group) will follow a supervised resistance training program for 8 weeks. Neuromuscular function of the knee extensor muscles, body composition, intramuscular adaptations, as well as blood profiles (hormonal and metabolic) and exosomes will be assessed before and after a single resistance exercise session and after the training period. This protocol will allow determination of both the acute and long-term effects of resistance exercise.

Women's participation in sports is increasing, yet research in this area remains very limited. This project aims to better understand the mechanisms by which resistance training-a non-pharmacological and low-cost strategy-may induce different adaptations in men and women, and, where appropriate, to contribute to the development of sex-specific recommendations to maximize the health benefits of resistance training.

Eligibility

Sex
ALL
Min age
18 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Men and women aged between 18 and 40 years; * eumenorrheic women or under contraceptive (hormonal and non-hormonal). Exclusion Criteria: * Regular resistance exercise (≥2x/week); * Any contraindication to exercise; * Protein/creatine supplement intake; * Pregnancy; * Epilepsy; * Head implant.

Primary outcome measure(s)

  • Sex differences in protein expression of muscle mass regulation pathways assessed by western blot — Throughout the entire study, during approximately 11 months
    Assessment of protein of expression muscle mass regulation pathways after acute exercise and chronic exercise using western blot (ratio of target protein to reference protein)
  • Sex differences in mRNA levels in muscle mass regulation pathways assessed by RT-qPCR — Throughout the entire study, during approximately 11 months
    Assessment of mRNA levels of muscle mass regulation pathways after acute exercise and chronic exercise usin RT-qPCR (fold change).
  • Sex differences in metabolic status assessed by blood biomarkers — Throughout the entire study, during approximately 11 months
    Assessment of metabolic blood parameters before and after acute exercise and chronic resistance training.
  • Sex differences in hormonal status assessed by blood biomarkers — Throughout the entire study, during approximately 11 months
    Assessment of hormonal blood parameters before and after acute exercise and chronic resistance training.
  • Sex differences in extracellular vesicles regulation assessed by nanoparticle tracking analysis — Throughout the entire study, during approximately 11 months
    Assessment of the concentration and size of circulating extracellular vesicles after acute exercise and chronic exercise using nanoparticle tracking analysis.
  • Sex differences in extracellular vesicles regulation assessed by proteomic analysis — Throughout the entire study, during approximately 11 months
    Assessment of protein expression of circulating extracellular vesicles after acute exercise and chronic exercise using proteomic analysis

Trial sites (1)

FacilityCityRegionStatus
Faculté des sciences de la motricité, Pl. Pierre de Coubertin 1 Louvain-la-Neuve Belgium
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07692815 on ClinicalTrials.gov ↗ ← All trials in Belgium